| 000 | 01874cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223030758.0 | ||
| 008 | 130228s2012 ua dh f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aM.Sc | ||
| 099 | _aCai01.12.02.M.Sc.2012.He.B | ||
| 100 | 0 | _aHeba Mohamed Mohamed Shehata | |
| 245 | 1 | 0 |
_aBiochemical studies of vascular endothelial growth factor in patients with liver diseases / _cHeba Mohamed Mohamed Shehata ; Supervised Abdelgawad Ali Fahmi , Mohamed Ali Eldesouky , Amal Mohamed Ahmed |
| 246 | 1 | 5 | _aدراسات كيميائية حيوية لعامل النمو للخلايا المبطنة للأوعية الدموية فى مرضى الكبد |
| 260 |
_aCairo : _bHeba Mohamed Mohamed Shehata , _c2012 |
||
| 300 |
_a132P. : _bcharts , facsimiles ; _c25cm |
||
| 502 | _aThesis (M.Sc.) - Cairo University - Faculty of Science - Department of Biochemistry | ||
| 520 | _aChronic infection with hepatitis C virus (HCV) is a well established risk factor for the development of hepatocellular carcinoma (HCC) and in many areas of the world is the predominant etiology for hepatocarcinogenesis . The prevalence of HCV infection varies throughout the world , the highest number of infections is reported in Egypt . HCV accounts for about 70% of cases with chronic hepatitis , 40% with cirrhosis , 60% with HCC and 15 - 30% of liver transplantation | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aHepatitis C virus | |
| 653 | 4 | _aHepatocellular carcinoma | |
| 653 | 4 | _aÜ - fetoprotein | |
| 700 | 0 |
_aAbdelgawad Ali Fahmi , _eSupervisor |
|
| 700 | 0 |
_aAmal Mohamed Ahmed , _eSupervisor |
|
| 700 | 0 |
_aMohamed Ali Eldesouky , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aFatma _eCataloger |
||
| 905 |
_aNazla _eRevisor |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c41770 _d41770 |
||